# Amgen Announces Positive Phase 3 Results for Sjögren’s Drug

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54942
Published: 2026-11-12T04:58:37.000Z
Updated: 2026-11-12T04:58:37.000Z
Section: Business

> The results came from the OASIZ-301 study of dazodalibep. Amgen plans to present the full findings at ACR Convergence 2026.

Amgen announced positive Phase 3 results Nov. 11 for dazodalibep, a therapy for Sjögren’s disease. The findings came from the OASIZ-301 study.

Amgen plans to present the full results at ACR Convergence 2026.